Peppermint VenturePartners (PVP) is a private Venture Capital firm based in Berlin, Germany. Grown out of Peppermint Holding, a mid-sized industry group, we are dedicated to supporting outstanding entrepreneurs and innovative scientists in transforming healthcare.
Along the continuum of care, we invest in disruptive and novel solutions that bring increased efficiency, improved accessibility, cost containment, and digitization of the healthcare system and the life science industry.
Investments in top tier transformative medtech, digital health and biotech companies bridging market boundaries.
Improving healthcare by bringing medical innovations to patients in local and international markets.
We firmly believe that investing in healthcare is much more than just providing funding for start-ups. Integrity, commitment and social responsibility are therefore strong pillars of our investment decisions.
We love working with dedicated founders and management teams in a collaborative way, supporting them with our unique experience and our strong network of relevant stakeholders in the healthcare sector.
We invest in early-stage healthcare companies along the continuum of care. Our focus is on disruptive innovations in ophthalmic and cardiovascular diseases.
This is us
Our team combines a longstanding history in funding, mentoring and developing transformative Life Science companies with operational business expertise ranging from international C-Level to entrepreneurial business building.
The combination of complementary skills and interdisciplinary technical expertise together with comprehensive national and international networks in the life science sector, allows PVP to support its portfolio companies in their development. The PVP team members have a track record working in various constellations on investments and exits of several start-ups in the field.
The PVP Advisory Board supports the team as a discussion partner on questions regarding the strategic development of the portfolio. It consists of experienced managers in the healthcare field, clinical experts and successful companies.
PVP has established longstanding relationships with leading research centers in Germany to support them in validating and translating their disruptive scientific ideas into medical solutions.
Since 2010 PVP has been collaborating with the Charité, one of the leading university clinics in Europe. PVP utilizes this relationship for its Peppermint Charité Biomedical Fund (CBF 1), which helps to promote translation of medical research into start-up ideas as well as provide access to a unique clinical research network for its portfolio companies.
In 2011 we started working with the Helmholtz Association, Germany’s largest research organization comprised of 18 centers with more than 43,000 employees and an annual budget of over € 5 billion.
Our sister company, PVP Advisors, carries out the external management of the Helmholtz Validation Fund (HVF), which funded 50 internal projects that bridge the gap between research results and their marketable applications.
In addition, PVP team members are deeply embedded as judges, mentors and coaches in a variety of relevant international start-ups initiatives, business plan competitions and funding networks like TechTour, EIT Health, EIC, etc.
Caterna Vision GmbH
The First Health App on Prescription for Kids with Lazy Eyes (Amblyopia)
Using Cryotherapy to Treat and Prevent Heart Attacks
ESYSTA - The Only Automatic and Seamless Digital Diabetes Monitoring Solution Integrating Insulin and Blood Glucose Data
Implandata Ophtalmic Products GmbH
Transforming Glaucoma Care through Remote Monitoring and Continuous Measuring of Intraocular Pressure
Building the Laboratory of the Future
Miracor Medical SA
Positively Changing the Course for Heart Attack Patients
CELLACT Pharma GmbH
CellAct Pharma GmbH is a venture backed biotech company focused on the development of innovative therapeutics for the treatment of diseases with high unmet need for certain cancers. CellAct's drug candidate CAP7.1 was purchased by MundiPharma.
A BICO Company. Global leader in precision dispensing. Enabling miniaturized multiplex assays for diagnostics and other fields of life sciences.
CEVEC Pharmaceuticals GmbH
High Performance Cell Technology For Advanced Biotherapeutics
The First Functional Liver Test LiMAX that Can Save Lives of Patients with Liver Diseases
Peppermint VC 1 Fund
Size: EUR 21 million
VC 1 was launched in 2000 by entrepreneurial Limited Partner with an industry background. With a volume of € 21 million, VC 1 built a portfolio of eight companies in ICT, industrial technologies and life sciences.
Within this portfolio, four investments were made in Life Sciences companies ranging from drug development to tools and services. Two of these companies were successfully exited.
One of these, Scienion AG, yielded a return of >13x for the fund.
VC 1 achieved a total return of >1.7x.
- Size: € 21 million
- Closing/ (Vintage): 2000
- Intervention: Early Stage
- Sectors: ICT, Industrial Technologies, Life Sciences
- Geography: Germany
- 8 investments
- Overall return: >1.7x
Peppermint Charité Biomedical Fund
Size: EUR 30 million
CBF 1 was launched in 2010 within the scope of the cooperation with Charité – Universitätsmedizin Berlin. With a volume of 30 million €, CBF 1 has built a portfolio of eight companies in the Healthcare sector. The focus of investments has been in the areas of ophthalmology and cardiology with four portfolio companies.
One company - Humedics GmbH - was created together with the Charité and three had clinical or business relationships during their development and validation.
The portfolio companies have attracted 185 million € from co-investors from all around the world leveraging CBF 1 investments by a factor of 9.4x.
- Size: € 30 million
- Closing/ (Vintage): 2011
- Intervention: Early Stage
- Sectors: MedTech, Digital Health, Pharma Platforms
- Geography: Europe with a focus on DACH
- 9 investments
- 6 active portfolio companies
Peppermint Lab Tech Fund
Size: Target Size EUR 100 million
Closing: Envisioned First Closing 2024
LIIDO (Laboratory Intelligence Innovations Digitalization and Operations)
The LIIDO Fund, aimed to launch in 2024 will invest in Future Market Leaders in the Life Science Tools & Services Space. With a target volume of a 100 Mio EUR, LIIDO will focus on investments in technology-driven companies with market traction and initial revenues.
As founder teams frequently lack go-to-market and execution capabilities the LIIDO team is set up to fill those gaps with providing experts and know-how for capability building, thereby accelerating revenue growth and access to tier 1 customer institutions and global partners.
- Target Size: € 100 million
- Envisioned First Closing: 2024
- Sectors: LabTech Tools & Services
- Geography: Europe with a focus on DACH, UK & Scandinavia